News2020-07-17T11:41:26-04:00
Oct 122022

Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum

October 12th, 2022|Categories: Investor News, News, Press Releases, Uncategorized|Tags: , , , |

Excess IL-6 is associated with inflammation in rheumatoid arthritis, MS, some cancers and neurodegenerative diseases. Jackson Center, PA, October 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies.  Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd’s earlier successful experiments, which eliminated IL-6 from cerebrospinal fluid (CSF) through exposure to laser irradiation, this recent experiment used an ...

Sep 272022

Halberd Enters Strategic Alliance for Longevity, Alzheimer’s Disease, and Cancer Early Detection, Prevention and Treatment

September 27th, 2022|Categories: Featured, Investor News, News, Press Releases|Tags: , , , , , , |

Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: "HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”.  The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease and Cancer treatments using the combined patented and patent-pending technologies of the alliance member companies.  The subsidiary will be staffed ...

Aug 232022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

August 23rd, 2022|Categories: Investor News, Medical, News, Press Releases|Tags: , , , , , , , , |

Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing.  PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the tumor to grow[1].  Halberd’s extracorporeal process, operating on blood serum, can potentially be used to eliminate PD-1 and allow the ...

Aug 42022

NFL Retired Players Association Endorses Halberd Brain Injury Treatment Technology

August 4th, 2022|Categories: Featured, Investor News, News|

Jackson Center, PA, August 04, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd’s research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players.  Traumatic brain injuries often progress to neurodegenerative diseases, such as PTSD, Alzheimer’s Disease, Parkinson’s Disease, Epilepsy and suicide ideation. The letter of endorsement ...

Jul 202022

Halberd Corp. Launches “Halberd Cancer Therapeutics, LTD” Wholly Owned Subsidiary

July 20th, 2022|Categories: Featured, Investor News, News|Tags: , , , , |

Jackson Center, PA, July 20, 2022 – Halberd Corporation (OTC-PINK: "HALB”) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary.  Halberd’s patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses.  For now, the new entity will be staffed by Halberd personnel until such time as business opportunities arise and appropriately skilled individuals are recruited to carry the subsidiary forward in its ...

Jul 142022

Halberd’s Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron

July 14th, 2022|Categories: Investor News, News, Press Releases|Tags: , , , , |

Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, PA, July 14, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron.  When Halberd’s antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness of the commercial antibody was increased from 65% to 94%.  This could lead to a treatment that is widely effective ...

Go to Top